IP Library Granted Patent US 9,840,456
Granted Patent B2
US 9,840,456 · App. 15/025,056 · Granted Dec 12, 2017

Process for preparation of dimethyl fumarate

Inventors: Shekhar Bhaskar Bhirud (Mumbai, IN); Kumar Hari Bhushan (Gurgaon, IN); H M Veerabhadra Swamy (Bangalore, IN); Dilipkumar Jibhau Patil (Nasik, IN); Avikumar Digambar Dabe (Nasik, IN)
Assignee: GLENMARK PHARMACEUTICALS LIMITED
C07C69/60C07C67/08C07C67/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,840,456
App. No.
15/025,056
Granted
Dec 12, 2017
Kind
B2
Abstract

The present invention relates to a process for the preparation of dimethyl fumarate, a compound of formula I, in a purity of at least 99.0% as determined by HPLC, containing less than 400 ppm of an anion of a mineral acid and less than 5 ppm of dimethyl maleate.

Claims (12)

1. A process for the preparation of dimethyl fumarate, a compound of formula I,

in a purity of at least 99.0% as determined by HPLC, containing less than 400 ppm of an anion of a mineral acid and less than 5 ppm of dimethyl maleate and having a D90 particle size of at least 400 μm, the process comprising:

(a) reacting fumaric acid with an acyl halide in methanol to obtain dimethyl fumarate, a compound of formula I, wherein a molar equivalent of the acyl halide is in the range of from about an equimolar amount to about 2 times the molar amount with respect to fumaric acid;

(b) subjecting dimethyl fumarate, the compound of formula I, to treatment with a base; and

(c) isolating dimethyl fumarate, the compound of formula I, from crystallization in a solvent, in a purity of at least 99.0% as determined by HPLC, containing less than 400 ppm of an anion of a mineral acid and less than 5 ppm of dimethyl maleate and having a D90 particle size of at least 400 μm.

2. The process of claim 1 , wherein the anion of a mineral acid is selected from the group consisting of chloride, bromide, iodide, fluoride, sulphate, nitrate and phosphate.

3. The process of claim 1 , wherein the isolated dimethyl fumarate, a compound of formula I, is free of dimethyl sulfate.

4. The process of claim 1 , wherein the isolated dimethyl fumarate is free of dimethyl sulfate and has a monomethyl fumarate content of less than 0.15%.

5. The process of claim 1 , wherein the solvent in step (c) is selected from the group consisting of an alcohol, an ester, a ketone, an ether, a haloalkane, acetonitrile; dimethyl sulfoxide; dimethyl formamide; dimethyl acetamide; water and mixtures thereof.

6. The process of claim 1 , wherein the solvent in step (c) is methanol.

7. The process of claim 1 , wherein the isolated dimethyl fumarate obtained in step (c) has a D90 particle size of 400 to 600 μm.

8. The process of claim 6 , wherein the isolated dimethyl fumarate is characterized by XRPD peaks at 2-theta 10.9, 22.0, 24.0 and 27.3±0.2°.

Assignments (4)
CHANGE OF NAME Recorded Jan 7, 2025
From: GLENMARK LIFE SCIENCES LIMITED
To: ALIVUS LIFE SCIENCES LIMITED
Reel/Frame 069775/0970 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2019
From: GLENMARK PHARMACEUTICALS LIMITED
To: GLENMARK LIFE SCIENCES LIMITED
Reel/Frame 050179/0351 →
MERGER Recorded Mar 31, 2017
From: GLENMARK GENERICS LIMITED
To: GLENMARK PHARMACEUTICALS LIMITED
Reel/Frame 042127/0063 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2017
From: BHIRUD, SHEKHAR BHASKAR; BHUSHAN, KUMAR HARI; SWAMY, H.M. VEERABHADRA; PATIL, DILIPKUMAR JIBHAU; DABE, AVIKUMAR DIGAMBAR
To: GLENMARK PHARMACEUTICALS LIMITED
Reel/Frame 040868/0665 →
Priority Claims (1)
IN 3070/MUM/2013 · Sep 25, 2013 · national
Continuity (1)
Related Publication 20160237021A1 · Aug 18, 2016